ArriVent BioPharma (AVBP) Institutional Ownership → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free AVBP Stock Alerts $17.70 -0.29 (-1.61%) (As of 05/10/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Institutional Ownership Changes (13F Filings) for ArriVent BioPharma (NASDAQ:AVBP)CurrentInstitutional OwnershipPercentage9.48%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$11.67MNumber ofInstitutional Sellers(last 12 months)0 Get AVBP Insider Trade Alerts Want to know when executives and insiders are buying or selling ArriVent BioPharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… ArriVent BioPharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/10/2024Vanguard Group Inc.648,735$11.59M0.0%N/A1.937% 5/1/2024 BNP Paribas Financial Markets4,659$83K0.0%N/A0.014% (Data available from 1/1/2016 forward) AVBP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of AVBP shares? During the previous two years, the following institutional investors and hedge funds held shares of ArriVent BioPharma shares: Vanguard Group Inc. ($11.59M), BNP Paribas Financial Markets ($83K).Learn more on AVBP's institutional investors. What percentage of ArriVent BioPharma stock is owned by institutional investors? 9.48% of ArriVent BioPharma stock is owned by institutional investors. Learn more on AVBP's institutional investor holdings. Which institutional investors have been buying ArriVent BioPharma stock? The following institutional investors have purchased ArriVent BioPharma stock in the last 24 months: Vanguard Group Inc. ($648.74K), and BNP Paribas Financial Markets ($4.66K). How much institutional buying is happening at ArriVent BioPharma? Institutional investors have bought a total of 653,394 shares in the last 24 months. This purchase volume represents approximately $11.67M in transactions. Related Companies: Aerovate Therapeutics Institutional Ownership Calliditas Therapeutics AB (publ) Institutional Ownership Y-mAbs Therapeutics Institutional Ownership IGM Biosciences Institutional Ownership Phathom Pharmaceuticals Institutional Ownership GH Research Institutional Ownership Stoke Therapeutics Institutional Ownership Pharming Group Institutional Ownership ORIC Pharmaceuticals Institutional Ownership Astria Therapeutics Institutional Ownership This page (NASDAQ:AVBP) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
